Breaking News, Collaborations & Alliances

BridGene Biosciences, Takeda Partner to Discover Small Molecule Drugs

Aim to advance novel small molecule drug candidates against challenging targets in immunology and neurology.

Author Image

By: Charlie Sternberg

Associate Editor

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use its chemoproteomics platform, IMTAC, to discover novel small molecule drug candidates against challenging targets in immunology and neurology. The companies will work together to advance these projects through hit finding and early lead development. Takeda will have exclusive rights to develop and commercialize any potential products identified through the collaboration. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters